Format

Send to

Choose Destination
Ann Oncol. 2011 Jan;22(1):156-64. doi: 10.1093/annonc/mdq310. Epub 2010 Jun 29.

Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study.

Author information

1
Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey. hoemonal@hotmail.com

Abstract

BACKGROUND:

this study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma.

PATIENTS AND METHODS:

data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months.

RESULTS:

sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC.

CONCLUSIONS:

combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

PMID:
20587509
DOI:
10.1093/annonc/mdq310
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center